What is Wedbush’s Estimate for SANA Q3 Earnings?

Sana Biotechnology, Inc. (NASDAQ:SANA) – Equities research analysts at Wedbush issued their Q3 2025 earnings per share estimates for Sana Biotechnology in a report issued on Wednesday, September 24th. Wedbush analyst M. Fan forecasts that the company will earn ($0.23) per share for the quarter. Wedbush has a “Outperform” rating and a $5.00 price target on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.16) per share. Wedbush also issued estimates for Sana Biotechnology’s Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.74) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.46) EPS, FY2028 earnings at ($0.44) EPS and FY2029 earnings at ($0.46) EPS.

A number of other research firms have also recently issued reports on SANA. Morgan Stanley started coverage on Sana Biotechnology in a research report on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Sana Biotechnology in a research report on Tuesday, June 24th. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Sana Biotechnology has a consensus rating of “Buy” and an average price target of $7.50.

Sana Biotechnology Stock Performance

NASDAQ:SANA opened at $3.39 on Friday. The company has a market cap of $806.18 million, a PE ratio of -3.20 and a beta of 1.88. Sana Biotechnology has a 52-week low of $1.26 and a 52-week high of $7.30. The stock has a 50-day simple moving average of $3.57 and a 200 day simple moving average of $2.75.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04.

Hedge Funds Weigh In On Sana Biotechnology

Large investors have recently made changes to their positions in the company. Marex Group plc bought a new position in Sana Biotechnology during the 2nd quarter worth $10,423,000. AQR Capital Management LLC increased its stake in Sana Biotechnology by 136.7% during the 2nd quarter. AQR Capital Management LLC now owns 1,356,363 shares of the company’s stock worth $3,703,000 after acquiring an additional 783,217 shares during the period. Corient Private Wealth LLC increased its stake in Sana Biotechnology by 264.7% during the 2nd quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock worth $3,101,000 after acquiring an additional 824,505 shares during the period. Bank of America Corp DE increased its stake in Sana Biotechnology by 11.3% during the 4th quarter. Bank of America Corp DE now owns 1,131,813 shares of the company’s stock worth $1,845,000 after acquiring an additional 115,347 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Sana Biotechnology by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,066,304 shares of the company’s stock worth $1,791,000 after acquiring an additional 9,792 shares during the period. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.